You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Exploring Data on Emerging Treatments for Primary Biliary Cholangitis

  • Authors: Gideon Hirschfield, MB BChir, PhD, FRCP (Lon); Marlyn Mayo, MD; Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD
  • CME / ABIM MOC / CE Released: 2/21/2023
  • Valid for credit through: 2/21/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hepatologists, gastroenterologists, primary care physicians, nurse practitioners, nurses/advanced practice nurses, physician assistants, and other clinicians who treat patients with PBC.

The goal of this activity is for learners to be better able to understand the physiologic targets of emerging PBC treatments and data from clinical studies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Targets of intervention for PBC in the context of disease pathophysiology
    • Data on PPAR-targeted agents for PBC
    • Endpoints used in clinical trials for emerging PBC treatments


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Gideon Hirschfield, MB BChir, PhD, FRCP (Lon)

    Professor of Medicine 
    Division of Gastroenterology and Hepatology
    University of Toronto
    Director, Autoimmune Liver Disease Program 
    Toronto Centre for Liver Disease
    Toronto, Ontario, Canada

    Disclosures

    Gideon Hirschfield, MB BChir, PhD, FRCP (Lon), has the following relevant financial relationships: 
    Consultant or advisor for: Cymabay Therapeutics; Escient; GlaxoSmithKline; HighTide; Intercept Pharmaceuticals, Inc.; Ipsen; Mirum; Pliant 
    Speaker or member of speakers bureau for: GlaxoSmithKline; Intercept Pharmaceuticals, Inc.; Ipsen

  • Marlyn Mayo, MD

    Professor of Internal Medicine
    UT Southwestern Medical Center
    Dallas, Texas, United States

    Disclosures

    Marlyn Mayo, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Cymabay Therapeutics; GlaxoSmithKline; Mallinckrodt Pharmaceuticals; Mirum; Target PBC
    Research funding from: Cymabay Therapeutics; GlaxoSmithKline; GENFIT SA; Intercept Pharmaceuticals, Inc.; Mallinckrodt Pharmaceuticals; Mirum; Salix Pharmaceuticals, Inc.; Target PBC

  • Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD

    Director, Liver Institute Northwest
    Professor of Medicine
    Elson S. Floyd College of Medicine
    Washington State University
    Seattle, Washington, United States

    Disclosures

    Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD, has the following relevant financial relationships: 
    Consultant or advisor for: 89bio; Cymabay Therapeutics; Enanta Pharmaceuticals, Inc.; GENFIT SA; Gilead Sciences, Inc.; HighTide; Inipharm; Intercept Pharmaceuticals, Inc.; Madrigal Pharmaceuticals, Inc.; Mirum; NGM Biopharmaceuticals; Pfizer Inc.
    Speaker or member of speakers bureau for: AbbVie, Gilead, Intercept
    Research funding from: 89bio; Corcept Therapeutics Inc.; Cymabay Therapeutics; GENFIT SA; Gilead Sciences, Inc.; GlaxoSmithKline; Hanmi Pharm Co., Ltd.; HighTide; Intercept Pharmaceuticals, Inc.; Madrigal Pharmaceuticals, Inc.; Mirum; Novo Nordisk; NGM Biopharmaceuticals; Pfizer Inc.; Pliant; Terns Pharmaceuticals; Viking
    Stock options from: Inipharm

Editors

  • Roderick Smith, MS

    Senior Medical Education Director, Medscape, LLC 

    Disclosures

    Roderick Smith, MS, has no relevant financial relationships.

  • Renata Feldman, PharmD

    Scientific Content Manager, Medscape, LLC 

    Disclosures

    Renata Feldman, PharmD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Exploring Data on Emerging Treatments for Primary Biliary Cholangitis

Authors: Gideon Hirschfield, MB BChir, PhD, FRCP (Lon); Marlyn Mayo, MD; Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLDFaculty and Disclosures

CME / ABIM MOC / CE Released: 2/21/2023

Valid for credit through: 2/21/2024, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Overview of PBC and its Pathophysiology

Join our expert faculty member as he discusses the latest in PBC.
Gideon Hirschfield, MB BChir, PhD, FRCP (Lon)

PPAR Agonists in PBC

Join Dr Mayo as she discusses advancements in PBC therapy.
Marlyn J. Mayo, MD

Other Emerging Targeted Therapies in PBC

Tune in to learn about novel clinical data and emerging PBC treatments.
Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD
 

Learning Feedback Questions

  • Print